| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10511111 | Gaceta Sanitaria | 2005 | 17 Pages |
Abstract
The creation of a single market for drugs in the EU should take this regulatory diversity into account and seek equilibrium between economic factors and public health. This single market may be a dangerous strategy if it becomes a general dogma and even more so if deadlines are fixed and short.
Related Topics
Health Sciences
Medicine and Dentistry
Public Health and Health Policy
Authors
Fernando Antoñanzas, Roberto RodrÃguez, José Antonio Sacristán, Rafael Illa,